Statistical challenges in the evaluation of surrogate endpoints in randomized trials.

The validation of surrogate endpoints has been studied by Prentice, who presented a definition as well as a set of criteria that are equivalent if the surrogate and true endpoints are binary. Freedman et al. supplemented these criteria with the so-called proportion explained. Buyse and Molenberghs proposed to replace the proportion explained by two quantities: (1). the relative effect, linking the effect of treatment on both endpoints, and (2). the adjusted association, an individual-level measure of agreement between both endpoints. In a multiunit setting, these quantities can be generalized to a trial-level measure of surrogacy and an individual-level measure of surrogacy. In this paper, we argue that such a multiunit approach should be adopted because it overcomes difficulties that necessarily surround validation efforts based on a single trial. These difficulties are highlighted.

[1]  P.T.V.M. de Jong,et al.  Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration , 1997 .

[2]  Thomas R. Fleming,et al.  Surrogate Endpoints in Clinical Trials , 1996 .

[3]  R. Prentice Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[4]  A. Fielding Sensitivity Analysis in Linear Regression , 1990 .

[5]  S. Ellenberg,et al.  Surrogate endpoints in clinical trials: cancer. , 1989, Statistics in medicine.

[6]  M Buyse,et al.  Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  C. Begg,et al.  On the use of surrogate end points in randomized trials , 2000 .

[8]  P Bacchetti,et al.  Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. , 1991, BMJ.

[9]  C. Begg,et al.  On the Use of Surrogate Endpoints in Randomized Trials (with Discussion) , 2000 .

[10]  Geert Molenberghs,et al.  Validation of Surrogate Endpoints in Multiple Randomized Clinical Trials with Discrete Outcomes , 2002 .

[11]  R J Carroll,et al.  On meta-analytic assessment of surrogate outcomes. , 2000, Biostatistics.

[12]  G. Molenberghs,et al.  The validation of surrogate endpoints in meta-analyses of randomized experiments. , 2000, Biostatistics.

[13]  J. Vermorken Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Dale Global cross-ratio models for bivariate, discrete, ordered responses. , 1986, Biometrics.

[15]  M J Daniels,et al.  Meta-analysis for the evaluation of potential surrogate markers. , 1997, Statistics in medicine.

[16]  G. Batist,et al.  Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  G. Molenberghs,et al.  Criteria for the validation of surrogate endpoints in randomized experiments. , 1998, Biometrics.

[18]  Robert Schooley,et al.  CD4+ Lymphocytes Are an Incomplete Surrogate Marker for Clinical Progression in Persons with Asymptomatic HIV Infection Taking Zidovudine , 1993, Annals of Internal Medicine.

[19]  B. Graubard,et al.  Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.

[20]  W. Guerra Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter , 1991 .

[21]  S. Duffy,et al.  Trial Design Based on Surrogate End Points — Application to Comparison of Different Breast Screening Frequencies , 1996 .

[22]  S. Weisberg,et al.  Residuals and Influence in Regression , 1982 .

[23]  N. Nair,et al.  Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The Risperidone Study Group. , 1998, Journal of clinical psychopharmacology.

[24]  G. Molenberghs,et al.  Validation of surrogate end points in multiple randomized clinical trials with failure time end points , 2001 .

[25]  Marc Buyse,et al.  Cyclophosphamide Plus Cisplatin Versus Cyclophosphomide, Doxorubicin, and Cisplatin Chemotherapy of Ovarian-carcinoma - a Metaanalysis , 1991 .

[26]  P. Hartigan,et al.  Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. , 1996, The New England journal of medicine.

[27]  J M Taylor,et al.  Statistical issues for HIV surrogate endpoints: point/counterpoint. An NIAID workshop. , 1998, Statistics in medicine.

[28]  M S Pepe,et al.  Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. , 1994, Statistics in medicine.

[29]  S. Chatterjee Sensitivity analysis in linear regression , 1988 .

[30]  V De Gruttola,et al.  Estimating the proportion of treatment effect explained by a surrogate marker. , 1997, Statistics in medicine.

[31]  Lewis A. Opler,et al.  Reliability and validity of the positive and negative syndrome scale for schizophrenics , 1988, Psychiatry Research.